3McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng J Med, 1998,339:1485-1492.
4Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol, 1999, 31(Suppl) :61-64.
5Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy.Science, 1998, 282:103-107.
6Wang YS, Youngster S, Bausch J, et al . Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry, 2000, 39:10634-10640.
7Monkarsh SP, Ma Y, Aglione A, et al. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Anal Biochem, 1997: 247:434-440.
8Heathcote EJ, Shiftman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Eng J Med, 2000,343:1673-1680.
二级参考文献15
1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.
6Harris J M,Martin N E,Modi M.Pegylation.a novel process for modifying pharmacokinetics.Clin Pharmaeokinet,2001,40:539.
7Kozlowski A,Charles S A,Harris J M.Development of pegylatedinterfemns for the treatment of chronic hepatitis C.Biodmgs,2001,15:419.
8Manns M p,Mehutehison J G,Cordon S C,et al.Peginterfemnet -2b plus ribavarin compared with interferon a-2b plus ribavirin for initiahreatment of chronic hepatitis C:a randomized trial.Lancet,2001,358 (9286):958.
9Fried M W,Shifman M L.Reddy K R,et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med,2002,347 (13):975.
10Jensen D M,Morgan T R,Marcellin P,et al.Early identification of HCV genotype 1 patients responding to 24 weeks poginterferon alpha-2a/ribavirin therapy.Hepatology,2006,43:954.
